InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Browse the full record of transactions filed by Saxonov Serge, Chief Executive Officer. Director active across 1 companies, notably 10x Genomics, Inc.. In total, 32 filings have been recorded. Total volume traded: €567k. The latest transaction was disclosed on 2 June 2022 — Don. Regulator: SEC (Form 4). All data is openly available.
Declarations32 total
01,651 shares0
Class A Common Stock
SEC:0001567619-22-012617:0·
€121,2472,656 shares@ €45.650.0058% mcap11.5% of flow
Class A Common Stock
SEC:0001567619-22-011714:0·
058,731 shares0
Class A Common Stock
SEC:0001567619-22-007438:0·
€38,294551 shares@ €69.49840.0018% mcap3.6% of flow
Class A Common Stock
SEC:0001567619-22-005521:0·
€30,4783,038 shares@ €10.03240.0015% mcap7.0% of flow
Class A Common Stock
SEC:0001567619-22-003272·
€30,4783,038 shares@ €10.03240.0015% mcap2.9% of flow
Class A Common Stock
SEC:0001567619-22-003272:0·
€30,8483,037 shares@ €10.15730.0015% mcap7.0% of flow
Class A Common Stock
SEC:0001567619-22-000817·
€30,8483,037 shares@ €10.15730.0015% mcap2.9% of flow
Class A Common Stock
SEC:0001567619-22-000817:0·
€59,69656,363 shares@ €1.05910.0029% mcap13.6% of flow
Class A Common Stock
SEC:0001567619-21-022725·
€59,69656,363 shares@ €1.05910.0029% mcap5.6% of flow
Class A Common Stock
SEC:0001567619-21-022725:0·
€23,2605,209 shares@ €4.46540.0011% mcap5.3% of flow
Class A Common Stock
SEC:0001567619-21-021857·
€23,2605,209 shares@ €4.46540.0011% mcap2.2% of flow
Class A Common Stock
SEC:0001567619-21-021857:0·
€101,590772 shares@ €131.59330.0049% mcap23.2% of flow
Class A Common Stock
SEC:0001567619-21-021186·
€101,590772 shares@ €131.59330.0049% mcap9.6% of flow
Class A Common Stock
SEC:0001567619-21-021186:0·
€22,6295,208 shares@ €4.3450.0011% mcap5.2% of flow
Class A Common Stock
SEC:0001567619-21-019360·
€22,6295,208 shares@ €4.3450.0011% mcap2.1% of flow
Class A Common Stock
SEC:0001567619-21-019360:0·
€22,6365,208 shares@ €4.34630.0011% mcap5.2% of flow
Class A Common Stock
SEC:0001567619-21-018030·
€22,6365,208 shares@ €4.34630.0011% mcap2.1% of flow
Class A Common Stock
SEC:0001567619-21-018030:0·
0360 shares0
Class A Common Stock
SEC:0001209191-21-055333·
0360 shares0
Class A Common Stock
SEC:0001209191-21-055333:0·
€102,253742 shares@ €137.80670.0049% mcap23.4% of flow
Class A Common Stock
SEC:0001209191-21-053393·
€102,253742 shares@ €137.80670.0049% mcap9.7% of flow
Class A Common Stock
SEC:0001209191-21-053393:0·
€22,1145,208 shares@ €4.24620.0011% mcap5.1% of flow
Class A Common Stock
SEC:0001209191-21-049657·
€22,1145,208 shares@ €4.24620.0011% mcap2.1% of flow
Class A Common Stock
SEC:0001209191-21-049657:0·
€22,1985,208 shares@ €4.26230.0011% mcap5.1% of flow
Class A Common Stock
SEC:0001209191-21-045995·
25 of 32 declarations
About Saxonov Serge
Serge Saxonov is the co-founder and Chief Executive Officer of 10x Genomics, a U.S.-listed company on Nasdaq (TXG) focused on single-cell and spatial biology. In this role, he leads corporate strategy, product innovation, and commercial execution. Public company materials describe him as a central architect of 10x Genomics’ growth, from its early startup phase through its IPO and subsequent expansion. He is also listed on the company’s leadership and board pages, underscoring his continuing role in governance and long-term direction. ([10xgenomics.com](https://www.10xgenomics.com/company/board/serge-saxonov?utm_source=openai)) Before founding 10x Genomics, Saxonov was part of the founding team at 23andMe, where he helped shape the company’s core product concepts and contributed to early technology and research-and-development strategy. He later served as Vice President of Applications at QuantaLife, which was acquired by Bio-Rad. In that position, he worked on application development, built content around ddPCR technology, and helped identify promising diagnostic areas. That career path reflects a blend of scientific depth, product thinking, and entrepreneurial execution. ([10xgenomics.com](https://www.10xgenomics.com/company/board/serge-saxonov?utm_source=openai)) His academic background further supports this profile: he earned an A.B. in Applied Mathematics from Harvard College and a Ph.D. in Biomedical Informatics from Stanford University. That combination has been especially relevant in a business operating at the intersection of biology, data, and instrumentation. Public profiles also note recognition for entrepreneurship and leadership, including honors from Goldman Sachs and the San Francisco Business Times. Overall, Serge Saxonov is widely associated with building and scaling technology platforms that have changed how researchers study biology, while guiding 10x Genomics through its transition into a public life sciences company with global scientific impact. ([10xgenomics.com](https://www.10xgenomics.com/company/board/serge-saxonov?utm_source=openai))
